Antibody-drug conjugates in acute myeloid leukemia: Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 5, 2006, Pages 238-239

  Scheinberg, David A ^a   Jurcic, Joseph G ^a   Maslak, Peter ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Remission; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; CALICHEAMICIN; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; LACTATE DEHYDROGENASE;

ACUTE GRANULOCYTIC LEUKEMIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER RESISTANCE; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DYSPNEA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; MONOTHERAPY; MULTIDRUG RESISTANCE; MYELOID PROGENITOR CELL; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SHORT SURVEY; THROMBOCYTOPENIA;

EID: 33646702574     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0478     Document Type: Short Survey

References (4)

1. Taussig DC et al. (2005) Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092
2. Sievers EL et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19: 3244-3245
3. Linenberger ML et al. (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98: 988-994
4. Jurcic JG (2005) Immunotherapy for acute myeloid leukemia. Curr Oncol Rep 7: 339-346